Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8197447 | 0.86 | ADRB2 (0.51) | ADRB2ALDH1A1HTR7TP53MAPK1 | |
| SCHEMBL203121 | 0.84 | ADRB2 (0.61) | PTPRCADRB2ALDH1A1HTR7TP53 | |
| SCHEMBL7673601 | 0.83 | TDP1 (0.45) | ADRB2ALDH1A1HTR7TP53MAPK1 | |
| Fluoride SCHEMBL27432507 | 0.82 | ADRB2 (0.59) | PTPRCADRB2ALDH1A1HTR7TP53 | |
| Propane SCHEMBL27542299 | 0.82 | ADRB2 (0.59) | PTPRCADRB2ALDH1A1HTR7TP53 | |
| SCHEMBL15966958 | 0.82 | KDM4E (0.49) | ADRB2ALDH1A1HTR7TP53MAPK1 | |
| SCHEMBL27324839 | 0.81 | PTPRC (0.58) | PTPRCADRB2GRM2ALDH1A1HTR7 | |
| SCHEMBL20703665 | 0.81 | ADRB2 (0.56) | ADRB2ALDH1A1HTR7TP53MAPK1 | |
| SCHEMBL27610647 | 0.81 | PTPRC (0.48) | PTPRCADRB2GRM2ALDH1A1HTR7 | |
| SCHEMBL29196085 | 0.80 | ALDH1A1 (0.44) | PTPRCALDH1A1L3MBTL1NPSR1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746390-A | Storage and transport stabilizers for polymerizable compounds | 巴斯夫欧洲公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2019028104-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ALPHALA CO., LTD. (TW) | 2019-02-07 | — | — | WO | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8389570-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8026371-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255214-A1 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080248506-A1 | Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | PTPRC 1832/4885ADRB2 4852/4885GRM2 4469/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PTPRC 1420/4885ADRB2 4882/4885GRM2 3672/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | PTPRC 3114/4885ADRB2 4291/4885GRM2 4800/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PTPRC 1420/4885ADRB2 4882/4885GRM2 3672/4885 |
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | PTPRC 2256/4885ADRB2 4533/4885GRM2 2965/4885 |
| US-20080255214-A1 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | PTPRC 1832/4885ADRB2 4852/4885GRM2 4469/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PTPRC 1420/4885ADRB2 4882/4885GRM2 3672/4885 |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | PTPRC 1420/4885ADRB2 4882/4885GRM2 3672/4885 |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | PTPRC 2659/4885ADRB2 4814/4885GRM2 4516/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | PTPRC 1832/4885ADRB2 4852/4885GRM2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.